Does real-world evidence still support intensive chemotherapy for high-risk AML?
Does real-world evidence still support intensive chemotherapy for high-risk AML?
Watch The VJSessions Roundtable Discussions
The VJ Sessions

Expert-led roundtable discussions on CLL, AML, MDS, MPNs, lymphoma, myeloma and amyloidosis

iwAL 2021

Watch iwAL 2021 presentations and discussions from global leaders on-demand now

VJSocial

Discover how you can leverage the power of Twitter in your professional life with our EHA social media masterclasses

Watch expert-led presentations & discussions from iwCAR-T 2021
iwCAR-T 2021

View expert-led presentations & discussions from all six sessions of the International Workshop on CAR-T 2021

Currently Trending
Watch Jorge Castillo discuss Novel agents for Waldenström’s macroglobulinemia 3:57
Novel agents for Waldenström’s macroglobulinemia
Jorge Castillo • 20 Aug 2021
Watch Ola Landgren discuss The mutagenic impact of melphalan in myeloma 2:34
The mutagenic impact of melphalan in myeloma
Ola Landgren • 23 Aug 2021
Watch Stephen Ansell discuss Updates on Cami-T for Hodgkin lymphoma 1:27
Updates on Cami-T for Hodgkin lymphoma
Stephen Ansell • 24 Aug 2021
Watch Angela Dispenzieri discuss Ongoing trials in amyloidosis 2:32
Ongoing trials in amyloidosis
Angela Dispenzieri • 18 Aug 2021
View Latest Videos by Disease
Watch the latest videos from the Multiple Myeloma Channel
Multiple Myeloma
Watch the latest videos from the Amyloidosis Channel
Amyloidosis
Watch the latest videos from the Lymphoma Channel
Lymphoma
Watch the latest videos from the Chronic Lymphocytic Leukemia Channel
Chronic Lymphocytic Leukemia
Watch the latest videos from the Acute Myeloid Leukemia Channel
Acute Myeloid Leukemia
Watch the latest videos from the Myelodysplastic Syndromes Channel
Myelodysplastic Syndromes
Watch the latest videos from the Myeloproliferative Neoplasms Channel
Myeloproliferative Neoplasms
Watch the latest videos from the Acute Lymphoblastic Leukemia Channel
Acute Lymphoblastic Leukemia
View all diseases
View more content
Trials
Medicines
Conferences
Features
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals